Close Menu

NEW YORK (GenomeWeb) – BGI has received the CE mark for its NIFTY cell-free DNA-based noninvasive prenatal test kit for fetal chromosomal aneuploidies on the BGISEQ-500 sequencing platform, the company said last week.

The test obtained EU medical device CE certification, issued by the British Standards Institution (BSI).

The NIFTY test estimates the risk of a fetus having trisomy 21, trisomy 18, and trisomy 13, sex chromosomal disorders, and certain deletion syndromes. It works by analyzing cell-free DNA from maternal blood at 10 weeks of gestation.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.